Cardiolite Side Effects

Please note - some side effects for Cardiolite may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Cardiolite Side Effects - for the Professional


Adverse events were evaluated in 3741 adults who were evaluated in clinical studies. Of these patients, 3068 (77% men, 22% women, and 0.7% of the patient’s genders were not recorded) were in cardiac clinical trials and 673 (100% women) in breast imaging trials. Cases of angina, chest pain, and death have occurred. Adverse events reported at a rate of 0.5% or greater after receiving Technetium Tc99m Sestamibi administration are shown in the following table:

Table 9
Selected Adverse Events Reported in > 0.5% of Patients Who Received Technetium
Tc99m Sestamibi in Either Breast or Cardiac Clinical Studies*
Body System Breast Studies Cardiac Studies
n = 673
n = 685
n = 2361
n = 3046
Body as a Whole    21 (3.1%)   6 (0.9%)   17 (0.7%)   23 (0.8%)
  Headache    11 (1.6%)   2 (0.3%)     4 (0.2%)    6 (0.2%)
Cardiovascular      9 (1.3%) 24 (3.5%)   75 (3.2%)   99 (3.3%)
  Chest Pain/Angina         0 (0%) 18 (2.6%)   46 (1.9%)   64 (2.1%)
  ST segment changes         0 (0%) 11 (1.6%)   29 (1.2%)   40 (1.3%)
Digestive System      8 (1.2%)   4 (0.6%)     9 (0.4%)   13 (0.4%)
  Nausea      4 (0.6%)   1 (0.1%)     2 (0.1%)     3 (0.1%)
Special Senses 132 (19.6%) 62 (9.1%) 160 (6.8%) 222 (7.3%)
  Taste Perversion 129 (19.2%) 60 (8.8%) 157 (6.6%) 217 (7.1%)
  Parosmia      8 (1.2%)   6 (0.9%)   10 (0.4%)   16 (0.5%)
*Excludes the 22 patients whose gender were not recorded.

In the clinical studies for breast imaging, breast pain was reported in 12 (1.7%) of the patients. In 11 of these patients the pain appears to be associated with biopsy/surgical procedures.

The following adverse reactions have been reported in ≤ 0.5% of patients: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis; angioedema, arrythmia, dizziness, syncope, abdominal pain, vomiting, and severe hypersensitivity characterized by dyspnea, hypotension, bradycardia, asthenia, and vomiting within two hours after a second injection of Technetium Tc99m Sestamibi. A few cases of flushing, edema, injection site inflammation, dry mouth, fever, pruritis, rash, urticaria and fatigue have also been attributed to administration of the agent.


Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.